文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

他克莫司对比吗替麦考酚酯用于一线治疗应答不完全的自身免疫性肝炎患者(TAILOR研究):一项III期、开放标签、多中心、随机对照试验的研究方案

Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.
PubMed 文献 · Trials · 2024-01-17

TAILOR研究是在荷兰教学与大学医院开展的III期B、多中心、开放标签、平行组、1:1随机对照试验,计划纳入86例一线治疗至少6个月未达完全生化应答的自身免疫性肝炎患者,随机接受他克莫司(初始0.07 mg/kg/天,按谷浓度调整)或吗替麦考酚酯(最大2000 mg/天),按入组时是否存在肝硬化分层,主要终点为12个月时达到完全生化应答的患者比例差异。

要点

  • TAILOR研究比较他克莫司与吗替麦考酚酯作为自身免疫性肝炎二线治疗的有效性与安全性。
  • 计划纳入86例一线治疗至少6个月未达完全生化应答的自身免疫性肝炎患者,1:1随机分组。
  • 主要终点为12个月时达到完全生化应答的患者比例差异。

核心结论

  • 本研究旨在比较他克莫司与吗替麦考酚酯作为自身免疫性肝炎二线治疗的有效性与安全性。
  • 这是首个比较两种自身免疫性肝炎二线治疗的随机对照试验。
  • 目前二线治疗基于回顾性队列研究。
  • 该试验结果可纳入现有国际临床指南。

研究设计与样本

  • TAILOR研究为III期B、多中心、开放标签、平行组、1:1随机对照试验,在荷兰大型教学与大学医院开展。
  • 计划纳入86例一线治疗至少6个月后未达到完全生化应答的自身免疫性肝炎患者。
  • 患者随机接受他克莫司(初始0.07 mg/kg/天,按谷浓度调整)或吗替麦考酚酯(最大2000 mg/天),按入组时是否存在肝硬化分层。
  • 主要终点为12个月时达到完全生化应答的患者比例差异。
  • 次要终点包括6个月时达到完全生化应答的患者比例差异、不良事件、纤维化生成差异、生活质量与成本效果。

关键数值与推荐

  • 完全生化应答定义为天冬氨酸转氨酶、丙氨酸转氨酶和免疫球蛋白γ正常化。
  • 他克莫司初始剂量为0.07 mg/kg/天,按谷浓度调整。
  • 吗替麦考酚酯最大剂量为2000 mg/天。
  • 一线治疗为硫唑嘌呤联合泼尼松龙。
  • 若未达到完全生化应答,他克莫司或吗替麦考酚酯可用作二线治疗。

临床怎么用

  • 他克莫司和吗替麦考酚酯均注册用于实体器官移植受者的移植物排斥预防。
  • 原文未据此给出推荐。

局限性

  • 自身免疫性肝炎的罕见性是替代治疗选择临床研究的主要问题。
  • 目前二线治疗基于回顾性队列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoimmune hepatitis (AIH) is a rare, chronic inflammatory disease of the liver. The treatment goal is reaching complete biochemical response (CR), defined as the normalisation of aspartate and alanine aminotransferases and immunoglobulin gamma. Ongoing AIH activity can lead to fibrosis and (decompensated) cirrhosis. Incomplete biochemical response is the most important risk factor for liver transplantation or liver-related mortality. First-line treatment consists of a combination of azathioprine and prednisolone. If CR is not reached, tacrolimus (TAC) or mycophenolate mofetil (MMF) can be used as second-line therapy. Both products are registered for the prevention of graft rejection in solid organ transplant recipients. The aim of this study is to compare the effectiveness and safety of TAC and MMF as second-line treatment for AIH. METHODS: The TAILOR study is a phase IIIB, multicentre, open-label, parallel-group, randomised (1:1) controlled trial performed in large teaching and university hospitals in the Netherlands. We will enrol 86 patients with AIH who have not reached CR after at least 6 months of treatment with first-line therapy. Patients are randomised to TAC (0.07 mg/kg/day initially and adjusted by trough levels) or MMF (max 2000 mg/day), stratified by the presence of cirrhosis at inclusion. The primary endpoint is the difference in the proportion of patients reaching CR after 12 months. Secondary endpoints include the difference in the proportion of patients reaching CR after 6 months, adverse effects, difference in fibrogenesis, quality of life and cost-effectiveness. DISCUSSION: This is the first randomised controlled trial comparing two second-line therapies for AIH. Currently, second-line treatment is based on retrospective cohort studies. The rarity of AIH is the main issue in clinical research for alternative treatment options. The results of this trial can be implemented in existing international clinical guidelines. TRIAL REGISTRATION: ClinicalTrials.gov NCT05221411 . Retrospectively registered on 3 February 2022; EudraCT number 2021-003420-33. Prospectively registered on 16 June 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Stoelinga AEC, Tushuizen ME, van den Hout WB, et al. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial. Trials. 2024. PMID: 38233878. doi:10.1186/s13063-023-07832-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。